Aurinia Pharmaceuticals

AUPH · NASDAQ

$16.74+$0.25 (+1.52%)TodayMarket closed · Oct 20, 7:58 PM ET

Prev close $16.49

Latest news

NewsAug 20, 9:30 AM ETVandana Singh
Aurinia Pharmaceuticals and Teva Settle Patent Dispute for Kidney Disease Drug
Press releaseAug 19, 4:05 PM ETBusiness Wire
Aurinia Settles Patent Litigation with Teva
NewsAug 6, 8:40 AM ET
Aurinia Pharmaceuticals Q2 EPS $0.28 Beats $0.24 Estimate, Sales $83.220M Beat $79.357M Estimate
Press releaseAug 6, 8:00 AM ETBusiness Wire
Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2026 and Provides Update on Recent Business Progress
Press releaseJul 6, 8:00 AM ETBusiness Wire
Aurinia Announces Initiation of PRESERVE, a Study Investigating the Combination of LUPKYNIS and Belimumab, Obinutuzumab or Anifrolumab in Patients with Lupus Nephritis
Press releaseJun 4, 7:00 AM ETBusiness Wire
LUPKYNIS Associated with a Statistically Significant 53% Reduction in Risk of Renal-Related Event or Death
NewsJun 3, 4:11 AM ET
Tang Capital Raises Aurinia Pharmaceuticals Holding to 10%
Press releaseJun 3, 12:43 AM ETPRNewswire
TANG CAPITAL MANAGEMENT, LLC FILES EARLY WARNING REPORT RESPECTING AURINIA PHARMACEUTICALS INC.
NewsMay 7, 8:14 AM ET
Aurinia Pharmaceuticals Q1 EPS $0.25 Beats $0.19 Estimate, Sales $77.705M Beat $77.390M Estimate
Press releaseMay 7, 8:00 AM ETBusiness Wire
Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2026 and Provides Update on Recent Business Progress
Press releaseMar 30, 8:00 AM ETBusiness Wire
Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.955 in Cash per Share Plus a Contingent Value Right
Press releaseMar 23, 11:00 AM ETBusiness Wire
MKT Capital Applauds Aurinia Pharmaceuticals' Management Transition
Press releaseMar 23, 8:00 AM ETBusiness Wire
Aurinia Announces Management Transition
NewsFeb 26, 4:06 PM ETHenry Khederian
Aurinia Pharmaceuticals (AUPH) Stock Drops After Strong Quarter, Softer Forward Revenue Targets
NewsFeb 26, 8:56 AM ET
Earnings Breakdown: Aurinia Pharmaceuticals Q4
NewsFeb 26, 6:11 AM ET
Earnings Scheduled For February 26, 2026
NewsFeb 26, 6:02 AM ET
Earnings Summary: Aurinia Pharmaceuticals Q4
NewsFeb 26, 6:01 AM ET
Aurinia Pharmaceuticals Q4 EPS $1.53, Sales $77.114M Beat $74.845M Estimate
Press releaseFeb 26, 6:00 AM ETBusiness Wire
Aurinia Pharmaceuticals Reports Financial Results for the Three and Twelve Months Ended December 31, 2025 and Provides Update on Recent Business Progress
NewsFeb 25, 1:02 PM ET
Earnings Preview: Aurinia Pharmaceuticals
Press releaseFeb 19, 6:00 AM ETBusiness Wire
Aurinia Pharmaceuticals to Report Financial Results for the Three and Twelve Months Ended December 31, 2025 and Provide Update on Recent Business Progress on February 26, 2026
Press releaseNov 4, 6:00 AM ETBusiness Wire
Aurinia Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2025 and Provides Update on Recent Business Progress
NewsNov 3, 6:58 AM ETVandana Singh
FDA Drug Chief George Tidmarsh Resigns After Allegations Of Power Misuse
Press releaseNov 3, 6:00 AM ETBusiness Wire
Aurinia Pharmaceuticals to Report Financial Results for the Three and Nine Months Ended September 30, 2025 and Provide Update on Recent Business Progress on November 4, 2025
Press releaseOct 15, 6:00 AM ETBusiness Wire
Aurinia Announces Upcoming Presentations of New Data on LUPKYNIS® at American College of Rheumatology Convergence and American Society of Nephrology Kidney Week 2025
Press releaseSep 29, 8:27 PM ETBusiness Wire
Aurinia Responds to Now Retracted LinkedIn Post
Press releaseJul 31, 6:00 AM ETBusiness Wire
Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2025
Press releaseJul 22, 6:00 AM ETBusiness Wire
Aurinia Pharmaceuticals to Release Second Quarter 2025 Financial and Operational Results on July 31, 2025
Press releaseJun 30, 6:00 AM ETBusiness Wire
Aurinia Announces Positive Results from Phase 1 Study of Aritinercept (AUR200)
Press releaseJun 29, 5:00 PM ETBusiness Wire
Aurinia Pharmaceuticals to Host Conference Call to Discuss AUR200 Phase 1 Study Results on June 30, 2025
NewsMay 23, 6:15 AM ETRishabh Mishra
US Stocks Likely To Open On A Mixed Note: 'Nothing Good Happens Above A 5% Yield,' Says Expert
Press releaseMay 22, 6:00 AM ETBusiness Wire
New AURORA 1 Analysis: LUPKYNIS-Based Triple Immunosuppressive Therapy Yields Deep Proteinuria Reduction in Lupus Nephritis
Press releaseMay 12, 6:00 AM ETBusiness Wire
Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2025
NewsMay 9, 11:02 AM ET
Uncovering Potential: Aurinia Pharmaceuticals's Earnings Preview
Press releaseMay 5, 6:00 AM ETBusiness Wire
Aurinia Pharmaceuticals to Release First Quarter 2025 Financial and Operational Results on May 12, 2025
Press releaseApr 30, 6:00 AM ETBusiness Wire
Glass Lewis Recommends That Aurinia Shareholders Vote "FOR" All Proposals at 2025 Annual General Meeting
Press releaseApr 29, 6:00 AM ETBusiness Wire
ISS Recommends That Aurinia Shareholders Vote "FOR" All Proposals at 2025 Annual General Meeting
Press releaseApr 23, 4:05 PM ETBusiness Wire
Concerned Shareholders of Aurinia Pharmaceuticals Announce Their Intention to Withhold Support for CEO Peter Greenleaf at 2025 Annual Meeting
Press releaseNov 7, 6:00 AM ETBusiness Wire
Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2024 Financial and Operational Results, Announces Strategic Restructuring to Sharpen Focus on Continued LUPKYNIS® Growth and AUR200 Development
NewsSep 24, 8:32 AM ET
Aurinia Announces Japan Approval Of LUPKYNIS To Treat Lupus Nephritis
Press releaseSep 24, 8:10 AM ETBusiness Wire
Aurinia Announces Japan Approval of LUPKYNIS® (Voclosporin) to Treat Lupus Nephritis
Press releaseAug 1, 6:00 AM ETBusiness Wire
Aurinia Pharmaceuticals Reports Second Quarter and Six Months 2024 Financial and Operational Results

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

Aurinia Pharmaceuticals and Teva Settle Patent Dispute for Kidney Disease Drug

Aurinia Settles Patent Litigation with Teva

Aurinia Pharmaceuticals Q2 EPS $0.28 Beats $0.24 Estimate, Sales $83.220M Beat $79.357M Estimate

Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2026 and Provides Update on Recent Business Progress

Aurinia Announces Initiation of PRESERVE, a Study Investigating the Combination of LUPKYNIS and Belimumab, Obinutuzumab or Anifrolumab in Patients with Lupus Nephritis

LUPKYNIS Associated with a Statistically Significant 53% Reduction in Risk of Renal-Related Event or Death

Tang Capital Raises Aurinia Pharmaceuticals Holding to 10%

TANG CAPITAL MANAGEMENT, LLC FILES EARLY WARNING REPORT RESPECTING AURINIA PHARMACEUTICALS INC.

Aurinia Pharmaceuticals Q1 EPS $0.25 Beats $0.19 Estimate, Sales $77.705M Beat $77.390M Estimate

Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2026 and Provides Update on Recent Business Progress

Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.955 in Cash per Share Plus a Contingent Value Right

MKT Capital Applauds Aurinia Pharmaceuticals' Management Transition

Aurinia Announces Management Transition

Aurinia Pharmaceuticals (AUPH) Stock Drops After Strong Quarter, Softer Forward Revenue Targets

Earnings Breakdown: Aurinia Pharmaceuticals Q4

Earnings Scheduled For February 26, 2026

Earnings Summary: Aurinia Pharmaceuticals Q4

Aurinia Pharmaceuticals Q4 EPS $1.53, Sales $77.114M Beat $74.845M Estimate

Aurinia Pharmaceuticals Reports Financial Results for the Three and Twelve Months Ended December 31, 2025 and Provides Update on Recent Business Progress

Earnings Preview: Aurinia Pharmaceuticals

Aurinia Pharmaceuticals to Report Financial Results for the Three and Twelve Months Ended December 31, 2025 and Provide Update on Recent Business Progress on February 26, 2026

Aurinia Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2025 and Provides Update on Recent Business Progress

FDA Drug Chief George Tidmarsh Resigns After Allegations Of Power Misuse

Aurinia Pharmaceuticals to Report Financial Results for the Three and Nine Months Ended September 30, 2025 and Provide Update on Recent Business Progress on November 4, 2025

Aurinia Announces Upcoming Presentations of New Data on LUPKYNIS® at American College of Rheumatology Convergence and American Society of Nephrology Kidney Week 2025

Aurinia Responds to Now Retracted LinkedIn Post

Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2025

Aurinia Pharmaceuticals to Release Second Quarter 2025 Financial and Operational Results on July 31, 2025

Aurinia Announces Positive Results from Phase 1 Study of Aritinercept (AUR200)

Aurinia Pharmaceuticals to Host Conference Call to Discuss AUR200 Phase 1 Study Results on June 30, 2025

US Stocks Likely To Open On A Mixed Note: 'Nothing Good Happens Above A 5% Yield,' Says Expert

New AURORA 1 Analysis: LUPKYNIS-Based Triple Immunosuppressive Therapy Yields Deep Proteinuria Reduction in Lupus Nephritis

Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2025

Uncovering Potential: Aurinia Pharmaceuticals's Earnings Preview

Aurinia Pharmaceuticals to Release First Quarter 2025 Financial and Operational Results on May 12, 2025

Glass Lewis Recommends That Aurinia Shareholders Vote "FOR" All Proposals at 2025 Annual General Meeting

ISS Recommends That Aurinia Shareholders Vote "FOR" All Proposals at 2025 Annual General Meeting

Concerned Shareholders of Aurinia Pharmaceuticals Announce Their Intention to Withhold Support for CEO Peter Greenleaf at 2025 Annual Meeting

Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2024 Financial and Operational Results, Announces Strategic Restructuring to Sharpen Focus on Continued LUPKYNIS® Growth and AUR200 Development

Aurinia Announces Japan Approval Of LUPKYNIS To Treat Lupus Nephritis

Aurinia Announces Japan Approval of LUPKYNIS® (Voclosporin) to Treat Lupus Nephritis

Aurinia Pharmaceuticals Reports Second Quarter and Six Months 2024 Financial and Operational Results